Exacerbated Neuropathy in POLAR A and M Trials Due to Redox Interaction of PledOx-Associated Mn<sup>2+</sup> and Oxaliplatin-Associated Pt<sup>2+</sup>

Exacerbated Neuropathy in POLAR A and M Trials Due to Redox Interaction of PledOx-Associated Mn<sup>2+</sup> and Oxaliplatin-Associated Pt<sup>2+</sup>

Disappointing results from the POLAR A and M phase III trials involving colorectal cancer patients on chemotherapy with FOLFOX6 in curative (A) and palliative (M) settings have been reported by the principal investigators and the sponsor (PledPharma AB/Egetis Therapeutics AB). FOLFOX6, oxaliplatin i...

Full description

Bibliographic Details
Main Authors: Jan Olof G. Karlsson, Per Jynge, Louis J. Ignarro
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Antioxidants
Subjects:
calmangafodipir (PledOx)
chemotherapy-induced peripheral neuropathy
clinical phase III trials
manganese
oxaliplatin
drug interaction
Online Access:https://www.mdpi.com/2076-3921/12/3/608

Internet

https://www.mdpi.com/2076-3921/12/3/608

Similar Items